Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 502,390 shares, a growth of 2,578.7% from the March 31st total of 18,755 shares. Approximately 11.4% of the company’s shares are short sold. Based on an average daily volume of 17,989,653 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ:GLMD opened at $0.63 on Friday. Galmed Pharmaceuticals has a 52-week low of $0.41 and a 52-week high of $2.68. The firm has a market capitalization of $3.44 million, a P/E ratio of -0.51 and a beta of 0.47. The stock has a 50 day moving average price of $0.62 and a 200-day moving average price of $0.87.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.